BIOMAT Database Logo BIOMAT Database Logo

The Management of Hepatitis B in Liver Transplant Recipients. 2016

Sammy Saab, and Ping-Yu Chen, and Clara E Saab, and Myron J Tong
Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA; Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA. Electronic address: SSaab@mednet.ucla.edu.

Liver transplant (LT) is now an established indication for patients with chronic hepatitis B, mainly because of the development and use of hepatitis B immunoglobulin (HBIG) and oral antivirals for prophylaxis. The combination of low-dose HBIG and antivirals has been considered the standard prophylaxis regimen to prevent post-LT recurrence of hepatitis B. The important remaining issues are related to the long-term cost of HBIG and the risk of escape hepatitis B virus (HBV) mutants. Strategies for prevention of HBV after LT are constantly improving. With the availability of new nucleoside/nucleotide analogues, new post-LT strategies also should emerge.

UI MeSH Term Description Entries
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D014943 Global Health A multi- and interdisciplinary field concerned with improving health and achieving equity in health for all people. It transcends national boundaries, promotes cooperation and collaboration within and beyond health science fields, and combines population-based disease prevention with individually-based patient care. International Health Problems,World Health,International Health,Worldwide Health,Health Problem, International,Health Problems, International,Health, Global,Health, International,Health, World,Health, Worldwide,Healths, International,International Health Problem,International Healths,Problem, International Health,Problems, International Health
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D016031 Liver Transplantation The transference of a part of or an entire liver from one human or animal to another. Grafting, Liver,Hepatic Transplantation,Liver Transplant,Transplantation, Hepatic,Transplantation, Liver,Hepatic Transplantations,Liver Grafting,Liver Transplantations,Liver Transplants,Transplant, Liver
D019468 Disease Management A broad approach to appropriate coordination of the entire disease treatment process that often involves shifting away from more expensive inpatient and acute care to areas such as preventive medicine, patient counseling and education, and outpatient care. This concept includes implications of appropriate versus inappropriate therapy on the overall cost and clinical outcome of a particular disease. (From Hosp Pharm 1995 Jul;30(7):596) Disease Managements,Management, Disease,Managements, Disease
D066027 Transplant Recipients Individuals receiving tissues or organs transferred from another individual of the same or different species, or from within the same individual. Recipient, Transplant,Recipients, Transplant,Transplant Recipient

Related Publications

Sammy Saab, and Ping-Yu Chen, and Clara E Saab, and Myron J Tong
Management of hepatitis B in liver transplant recipients.
November 2007, Journal of viral hepatitis,
Sammy Saab, and Ping-Yu Chen, and Clara E Saab, and Myron J Tong
Hepatitis B in liver transplant recipients.
November 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,
Sammy Saab, and Ping-Yu Chen, and Clara E Saab, and Myron J Tong
Management of viral hepatitis in liver transplant recipients.
December 2014, Clinical and molecular hepatology,
Sammy Saab, and Ping-Yu Chen, and Clara E Saab, and Myron J Tong
Management of hepatitis C in liver transplant recipients.
March 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Sammy Saab, and Ping-Yu Chen, and Clara E Saab, and Myron J Tong
Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients.
November 2015, World journal of gastrointestinal pharmacology and therapeutics,
Sammy Saab, and Ping-Yu Chen, and Clara E Saab, and Myron J Tong
Management of hepatitis B virus infection in liver transplant recipients: prospects and challenges.
January 2000, Clinical transplantation,
Sammy Saab, and Ping-Yu Chen, and Clara E Saab, and Myron J Tong
Management of recurrent hepatitis C in liver transplant recipients.
March 2006, Infectious disease clinics of North America,
Sammy Saab, and Ping-Yu Chen, and Clara E Saab, and Myron J Tong
Individualizing hepatitis B infection prophylaxis in liver transplant recipients.
September 2011, Journal of hepatology,
Sammy Saab, and Ping-Yu Chen, and Clara E Saab, and Myron J Tong
Hepatitis B vaccination results in 140 liver transplant recipients.
January 1997, Hepato-gastroenterology,
Sammy Saab, and Ping-Yu Chen, and Clara E Saab, and Myron J Tong
Treatment of recurrent hepatitis B infection in liver transplant recipients.
October 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,
Copied contents to your clipboard!